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Abstract:
Objectives: Interferon alpha-2b therapy for Chronic Hepatitis C
patients has been unsatisfactory. Recombinant Granulocyte Mac
rophage Colony-Stimulating Factor has been shown to have anti-
viral effects in vivo and in vitro via cytokines l23 Recently its
effects on chronic hepatitis B and possibly chronic hepatitis C were
reported.4’5 We, decided to conduct a pilot study to evaluate the
anti-viral effects of recombinant human GM-CSF mono-therapy in
patients with chronic hepatitis C and to assess its side effects,
Methods: A total of 10 patients (male/female: 5/5) (age: 34-60,
mean: 45) seen in our center between 2/95 to 2/96 were randomly
selected to receive recombThant human Granulocyte Macrophage
Colony-Stimulating-Factor at 125 ug/m2 subcutaneously daily for
two weeks followed by three times weekly for another 8 weeks.
Biochemical (ALT) and viral (HCV-RNA) responses were measured
prior to treatment and at weeks four and eight. Side effects were
recorded.
Results: Six out of the ten patients treated had significant viral
reduction but none became negative. Eight out the ten patients
treated showed biochemical improvement and three out of the eight
had normalized liver enzymes. Age, sex, stage of the disease did
not influence the response but there seems to be a tendency for
patients with higherpre-treatment viral level to respond virally. Side
effects are minimal and well-tolerated.
Conclusion: Recombinanthuman Granulocyte Macrophage Colony-
Stimulating-Factor in the dose used has anti-viral effects in the
majority of the chronic hepatitis C patients studied. Side effects are
minimal and well tolerated. Further study with higher doses and
longer duration is needed to prove its clinical efficacy in treating
patients with chronic hepatitis C.
Introduction:
In the past few years since interferon alpha 2-b (JFN) was licensed
for treatment of some patients with chronic hepatitis C, it has
become clear that standard IFN therapy (3 million units subcutane
ously three times a week) produces a complete biochemical re
sponse in 50% of patients (normalization of ALT at the end of
treatment); however, the majority of responders relapsed after
termination of therapy. To improve these results, many therapies
have been tried including retreatment with same dose or escalating
interferon dosage, iron depletion therapy, and prolonged interferon
therapy, but the beneficial results have not yet been established.
Among the different groups of biological response modifiers,
GM-CSF (Granulocyte Macrophage-Colony Stimulating Factor) is
a hormone-like glycoprotein cytokine produced by activated T
lymphocytes, endothelial cells and fibroblasts that stimulates the
proliferation, maturation and function of hemopoietic cells, aug
ments and modifies the immune system, and regulates the secretion
of other cytokines which are involved in the immune response to
viral hepatitis. Recently J. Martin. et al reported HBV-DNA level
reduction with GM-CSF alone or in combination with interferon
alfa-2b.2 Furthermore, in vitro studies of cytokine production by
PBMC(peripheral blood mononuclear cells) during GM-CSF treat
ment revealed enhanced spontaneous production of other cytokines.’
In the treatment of chronic hepatitis C, recombinant GM-CSF has
been used mainly to rescue leukopenic patients during treatment
with interferon alpha 2-b. There has been no clinical study in the
U.S. to investigate if recombinant GM-CSF by itself has any anti-
viral effect against hepatitis C virus. Therefore we decided to
conduct a pilot study treating chronic hepatitis C patients who failed
previous interferon alfa 2-b therapy with recombinant GM-CSF
alone to observe if there is any anti-HCV effect and to assess its side
effects.
Patients and Methods:
Ten patients (five males) with a mean age of 45 yr. (Range 34-60)
who were seen in a tertiary center between 2/95 to 2/96 were selected
to participate in this trial. The patient’s clinical characteristics can be
seen in Table I. All patients had failed previous interferon therapy
and were off interferon or other immunological therapy for at least
six months and met the inclusion and exclusion criteria. The proto
col was approved by the IRB of the institution. Consent forms were
signed. After the initial screening visit, all participants received
recombinant GM-CSF (manufactured by Immunex Co. Seattle,
Washington) at 125 ug/m2 subcutaneously daily for two weeks
followed by three times a week for another eight weeks. Biochemi
cal (ALT) and viral response (b-DNA method from Chiron Inc.
Summerville, California) were assessed prior to treatment and at
week four and eight. Side effects were assessed in each follow-up
visit and recorded.
Results:
Of the ten patients treated with GM-CSF, six had significant viral
titer reduction during the first two weeks of daily subcutaneous
injection. However, none had eradicated the virus. Eight out of the
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ten treated showed ALT improvement and among them three had
normalized ALT. The clinical data of all ten patients are shown in
Table 1. Three are genotype la, three type ib, one type 2b and three
untypable. Six patients had advanced liver disease and the remain
ing four had mild to moderate disease. Age, sex, stage of disease did
not influence the response but there seems to be a tendency for
patients with higher viral level to respond. Fig. I, Fig. ha and JIb
show mean HCV-RNA and ALT level of each patient respectively.
Side effects were minimal and well tolerated. The most common
side effect was injection site irritation. Other side effects included
flu-like symptoms (which were milder than that of interferon alpha
2-b) and general malaise. Two patients experience urticaria which
responded to anti-histamine treatment. No cardiopulmonary side
effects such as CHF or asthma attack were noted. Leukocytosis
responses were universal and several patients had eosinophilia (up
to 40% in one case with urticaria) but dose reduction was not needed.
Discussion:
Interferon therapy for chronic hepatitis C has been unsatisfactory
in attaining sustained response in the majority of patients. Clearly
enhancement of the response rate is needed. Of all the anti-viral
therapies, interferons were the only agents shown to have anti-viral
effect on hepatitis C virus. Ribavirin and Corticosteroids as
monotherapy have been tested but without success in eradication of
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Table 1.—Patient Charactestics
PreRx
Patient Sex Age Genotype Histology RNA(io’)
D.H. M 57 lb CAH >570
E.J. F 35 la CPH 326.9
FT. M 42 la CPH 68.6
FR. M 45 CAH 41.8
L.Y. F 59 lb Cirrhosis 167.5
K.G. F 34 la CPH 188.1
ML. F 49 4a Cirrhosis Not Done
CD. M 35 3a CPH 133.7
R.J. M 39 2b Cirrhosis <3.5
S.L. F 60 lb CPH 46.9
CAH = Chronic Active Hepatitis
CPH = Chronic Persistent Hepatitis
Figure I.— HCV-RNA Level Changes During Treatment (x!00,000 Copies/mi.) Patients HCV-RNA level pre- and during GM-CSF therapy. No patient has
eradicated HCV-RNA but there seems to be a downward trend in the level of HVC-RNA especially in the first four weeks of therapy when daily GM-C
SF was
administered. (Chiron version 1.0 Quantiplex method).
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the virus. GM-CSF has been used to rescue patients with leukopenia
on high dose interferon therapy4but its efficacy as monotherapy for
the treatment of chronic hepatitis C has not been tested. In this study
we administered rhGM-CSF to ten patients who have failed previ
ous interferon alpha 2-b treatment to study its anti - HCV effect and
to assess side effects. The dosage given is low at 125 mcg/m2
subcutaneously. The therapy was well tolerated with no significant
side effects. No dose reduction was needed and no patient withdrew
from the study. The leukocytosis occurred as expected and eosino
philia was observed in two patients. Local injection site irritation
was common but generally manageable. Other side effects such as
flu-like symptoms were much milder compared to that of the
interferon therapy these patients had experienced previously, even
during the daily rhGM-CSF administration in the first two weeks of
the trial.
The reduction in the viral RNA during the treatment was signifi
cant in the majority of the patients especially during the daily dosing
period. ALT was also noted to have improved in eight of the ten
patients with normalization in three patients. These effects may be
due to cytokine production by the GM-CSF effect. GM-CSF has
been shown to increase the liberation ofTNF-alpha (Tumor Necrosing
Factor Alpha), Interleukin-21’23which themselves have potent anti-
viral activity.6’78
In summary, the administration of rhGM-CSF in the doses used is
safe and well tolerated. The treatment seems to exert an anti-viral
effect on patients with chronic hepatitis C infection. Future studies
with higher dosage and longer duration of therapy or in combination
with interferon therapy are needed to prove its clinical efficacy as an
alternative and br adjuvant therapy for patients with chronic hepa
titis C. GM-CSF could also play a role in the treatment of those
patients with chronic hepatitis C who have significant leukopenia
and were excluded from interferon therapy.
Acknowledgment: The authors would like to thank Dr. Rodney Williams for his idea
and helpful criticism, to Mr. Peter Hsin and Ms. Sharon Lai for their technical
assistance.
References:
1. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage
colony-stimulating factor (part I). N Engi J Med 1992;327:28-35,
2. Martin J, Bosch 0, Moraleds 6, at al. Pilot Study of Recombinant Human Granulocyte-macrophage
Colony-stimulating Factor in the Treatment of Chronic Hepafitis B. Hepatology 1 993; 18:775-80.
3. Martin J, Guiroga JA, Baltolome J, at al. Antiviral Effect of Recombinant Human Granulocyte
niacrophage Colony.stimulating Factor in PBMCs of Patients with Chronic Hepatitis B. Hepatology
1993; 18(Part ll):118A
4. Martin J, QuirogaJA, Bosch 0, etal. Changes in Cytokine Production Duhng Therapy with Granulocyte
macrophage Colony-stimulating Factorin Patients with Chronic Hepatitis B. Hepafology 1994:20:1156-
61
5. Carreno V, Quiroga JA. Biological Response Modifiers in Chronic Hepatitis C. J. Hepatol. 1995;
22(Suppl. l(: 122-26
6. Koff WC, Fans AV. Human Tumor Necrosis Factor-Alpha Kills Herpes Virus-infected but not Normal
Cells. Lymphokines Res, 1988;5:215-21
7. Tug H, Vogel W, Tratkiawicz JA, at al. Pilot Study of Natural Human lnterleukin-2 in Patients with
Chronic Hepatitis B. lmmsnomodulatory and Antiviral Effects. J. Hepatol 1993;19:259-67
8. Hladik F, Tratkiewicz JA, Tilg H. at al. Biologic Activity of Low Dose lL-2 Treatment in Vivo. Molecular
Assessment of Cytokine Network Interaction. J. Immunol 1 994;1 53:1449-54
At the Mauna Kea Resort, we
recommend a daily round of golf
on two championship courses.
We also advise world-class dining,
two of Hawaii’s best beaches, and the
shared amenities of a timeless resort.
When it comes time for your meeting,
we offer spectacular indoor and out
door settings, state-of-the-art facilities,
and a professional staff to assist you
with your special needs. To find out
how we can make your next meeting
unforgettable, call 1-800-735-1111.
HAPuNA BEACH PRINCE HoTEL
www.hapunabeachprincehotel.com
*
LJS’,J( ICE1 13EaCH HOTEL
www.maunakeabeachhotel.com
HOWE,, PE,NCE HOTEL WAdK,ic, I MAO, PR,TJCE HOTEL
BEACH pn,NCE HatELMauNa SEA BEACH HOTEL
PRINCE RESORTS HAWAII
HAWAII MEDICAL JOURNAL, VOL 58. APRIL 1999
88
